atopic dermatitis

FDA stop sign
Biotech

Rapt's share price sinks after shelving AD drug under FDA hold

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is a a phase 2 oncology med called tivumecirnon.
James Waldron Nov 11, 2024 9:44am
target reach ladder climb meet win beat competition

Amgen reports first phase 3 win for $400M eczema drug

Sep 25, 2024 5:50am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Connect reduces China workforce, mulls strategy for asthma drug

Sep 6, 2024 4:37am
photo of a sign labeled closed on a business window

Aslan’s dream of challenging Dupixent dies as biotech winds down

Jul 17, 2024 8:36am
ice cream scoop cone

J&J scoops up another atopic dermatitis drug for $1.25B

May 28, 2024 8:30am
Deal terminate tear up end deal scrap

Connect uncouples from Pfizer by scrapping eczema pact

Apr 17, 2024 6:38am